Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125814703 | 12581470 | 3 | F | 20160331 | 20160912 | 20160721 | 20160920 | EXP | FR-ASTRAZENECA-2016SE75785 | ASTRAZENECA | 21532.00 | DY | F | Y | 0.00000 | 20160920 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125814703 | 12581470 | 1 | PS | FASLODEX | FULVESTRANT | 1 | Intramuscular | 1500 | MG | Y | U | 21344 | 500 | MG | INJECTION | /month | |||
| 125814703 | 12581470 | 2 | SS | PALBOCICLIB | PALBOCICLIB | 1 | Oral | 125 MG CYCLIC (DAILY, 3 WEEKS ON/1 WEEK OFF) | Y | 0 | CAPSULE | ||||||||
| 125814703 | 12581470 | 3 | SS | PALBOCICLIB | PALBOCICLIB | 1 | Oral | 125 MG DAILY | Y | 0 | CAPSULE | ||||||||
| 125814703 | 12581470 | 4 | SS | PALBOCICLIB | PALBOCICLIB | 1 | Oral | 125 MG DAILY | Y | 0 | CAPSULE | ||||||||
| 125814703 | 12581470 | 5 | C | ESIDREX | HYDROCHLOROTHIAZIDE | 1 | Oral | 0 | 1 | DF | QD | ||||||||
| 125814703 | 12581470 | 6 | C | KERLONE | BETAXOLOL HYDROCHLORIDE | 1 | Oral | 0 | 20 | MG | QD | ||||||||
| 125814703 | 12581470 | 7 | C | LERCANIDIPINE | LERCANIDIPINE | 1 | Oral | 0 | 10 | MG | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125814703 | 12581470 | 1 | Breast cancer metastatic |
| 125814703 | 12581470 | 2 | Breast cancer metastatic |
| 125814703 | 12581470 | 3 | Breast cancer metastatic |
| 125814703 | 12581470 | 4 | Breast cancer metastatic |
| 125814703 | 12581470 | 5 | Hypertension |
| 125814703 | 12581470 | 6 | Hypertension |
| 125814703 | 12581470 | 7 | Hypertension |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125814703 | 12581470 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125814703 | 12581470 | Anaemia | |
| 125814703 | 12581470 | Neutropenia | |
| 125814703 | 12581470 | Phlebitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125814703 | 12581470 | 1 | 20160311 | 20160515 | 0 | |
| 125814703 | 12581470 | 2 | 20160311 | 20160701 | 0 | |
| 125814703 | 12581470 | 3 | 20160705 | 20160728 | 0 | |
| 125814703 | 12581470 | 4 | 20160809 | 20160828 | 0 | |
| 125814703 | 12581470 | 7 | 201512 | 0 |